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because it was operative; the physician-accoucheurs
claimed that obstetrics and gynaecology belonged
together. As we know, the surgeons won the argument.
By the 20th century the obstetrician-gynaecologist
(who often, but not necessarily, possessed the FRCS)
became another kind of doctor who was always
addressed as Mr. And this is more or less the position
today; but is the persistence of this tradition sensible?
Fifty years ago it was relatively simple. Physicians
treated medical diseases and surgeons operated. Today,
the treatment of surgical disorders is often undertaken
by teams of doctors any of whom may “intervene” in a
technical or surgical manner (the interventional
radiologists are an example), whether they are titled Dr
or Mr, Miss, Mrs, or Ms. Thus patients with cancer who
happen to be sticklers for addressing people correctly
may well be puzzled when they are referred by Dr A,
their general practitioner, to Dr B, an oncologist, and
Dr C, a radiologist, before seeing Mr or Ms D, a
surgeon. An operation is performed under an
anaesthetic administered by Dr E after which the
patient is referred to Dr F for radiotherapy and back to
Dr B for chemotherapy depending, perhaps, on the
findings of a pathologist, Dr G. Further, the patient may
enter a controlled trial run by a medical statistician, Dr
H, who is not medically qualified but has a PhD.
That is eight “Drs” to one “Mr (or Miss or Mrs or
Ms).” Note that any of these doctors, including Mr B,
might possess an MD or a DM, which often puzzles
American doctors who are not always aware that in the
United Kingdom these are postgraduate degrees. But
whether or not they have been awarded a university
doctorate (an MD, DM, DPhil, or PhD) is irrelevant to
how they are addressed. Only the surgeon is addressed
as Mr (or Miss or Mrs or Ms), together with his or her
registrar; but the house surgeon is not, for it is (or used
to be) considered bad form if Dr John Jones who was a
house physician yesterday insists on being called Mr
Jones when taking up the house surgeon post
tomorrow.
Medical qualifications in the United Kingdom have
been in an unholy muddle ever since the Medical Act
of 1858 when no less than 18 independent medical
institutions offered a range of bachelorships, licences,
diplomas, memberships, fellowships, and doctorates all
officially recognised by the General Medical Council.
This cannot be altered. Now, however, so much of sur-
gery is teamwork that it seems to me that the original
and rather trivial reasons for “mistering” surgeons have
disappeared. Would surgeons be willing to abandon
this pretentious anachronism so that all who possess a
medical qualification that is recognised by the General
Medical Council, regardless of the specialty and the
letters after their name, are simply addressed as Dr?
It is at least worth considering.
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The discovery of aspirin: a reappraisal
Walter Sneader
The discovery of aspirin is customarily said to have
resulted from Felix Hoffmann’s rheumatic father
encouraging his son to produce a medicine devoid of
the unpleasant effects of sodium salicylate. Hoffmann,
a chemist in the pharmaceutical laboratory of the Ger-
man dye manufacturer Friedrich Bayer & Co in Elber-
feld, consulted the chemical literature and came across
the synthesis of acetylsalicylic acid and then prepared
the first sample of pure acetylsalicylic acid on 10
August 1897. This was marketed in 1899 under the
registered trademark of Aspirin. This account of the
discovery first appeared in 1934 as a footnote in a his-
tory of chemical engineering written by Albrecht
Schmidt, a chemist who had recently retired from IG
Farbenindustrie—the organisation into which F Bayer
& Co had been incorporated in 1925.1
Challenge to the accepted account
The footnote also stated that Hoffmann had arranged
for several chemical derivatives of salicylic acid to be
Summary points
Until now, it has been generally accepted that
Felix Hoffmann developed aspirin to help his
rheumatic father
In 1949 Hoffman’s former colleague Arthur
Eichengrün claimed that the work had been done
under his direction
Analysis of relevant archival and published
material now supports Eichengrün’s claim and
throws doubt on the reliability of the source
crediting Hoffmann
It is likely that acetylsalicylic acid was synthesised
under Eichengrün’s direction and that it would
not have been introduced in 1899 without his
intervention
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examined, not just its acetyl ester. No indication was
given of what the others were, but in 1899 Heinrich
Dreser, head of the experimental pharmacology
laboratory at Elberfeld, named them in a paper as pro-
pionyl, butyryl, valeryl, and benzoyl salicylic acids.2 He
further alluded to them in 1907,3 and again in 1918.4
No earlier reports of the preparation of any of these
are to be found, but three of them appear in a British
patent awarded on 3 March 1900 to Hoffmann’s
colleague Otto Bonhoeffer,5 and there is also a United
States patent for propionylsalicylic acid, again in the
name of Bonhoeffer.6 The award of these patents is
indicative of the absence of any prior mention of these
compounds in the literature. It must therefore be con-
cluded that the 1934 footnote is unreliable since it
clearly stated that Hoffmann had examined “prepara-
tions of salicylic acid derivatives which remained
unnoticed amongst several prepared a long time
before for other purposes.” The patents show that the
derivatives were newly prepared for the specific
purpose of finding a salicylic acid derivative that would
be of therapeutic value. Is then the remainder of the
footnote to be believed?
Laboratory reports of Hoffmann and
Dreser
The page on which Hoffmann reported his synthesis of
pure acetylsalicylic acid in 1897 is retained in the
archives of Bayer AG in Leverkusen. The significance
of the final sentence on it—“Durch ihre physikalischen
Eigenschaften wie eine sauren Geschmack ohne jede
Ätzwirkung unterscheidet sich die Acetylsalicylsäure
vorteilhaft von der Salicylsäure und wird dieselbe in
diesem Sinne auf ihre Verwendbarkeit geprüft”—has
been overlooked.
The correct translation is: “Due to its physical
properties, such as an acid taste without any corrosive
action, acetylsalicylic acid differs advantageously from
salicylic acid and is being examined for its usefulness
with just this in mind.” The German is, however, gram-
matically awkward and the sentence is capable of being
misread to mean that the compound was about to be
tested rather than that it was being tested. The most
likely interpretation, however, is that testing of
acetylsalicylic acid was already taking place at the time
Hoffmann wrote.
In a commemorative volume marking Bayer’s 50th
anniversary Arthur Eichengrün, a colleague of
Hoffmann, pointed out that after examining acetylsali-
cylic acid Dreser had set it aside for nearly 18 months
until he once again became involved with it in 1898.7
This statement was never disputed by Dreser, who
contributed the next article in the same publication.4
A recent Bayer publication notes, too, that Hoffmann
had repeatedly told his colleagues that Dreser had set
acetylsalicylic acid aside.8 Because Dreser did not
begin to write laboratory reports until 16 May 1898
there is no record of his testing salicylic acid
derivatives in 1897. However, his laboratory notebook
shows that on 27 September 1898, and three more
times that year, he investigated acetylsalicylic acid on
its own. If there was an interval of nearly 18 months
between Dreser’s first and later experimenting with
acetylsalicylic acid, this interval obviously could not
have ended much before 27 September 1898, since he
took up his appointment at Elberfield on 1 April 1897.
His initial work testing salicylic acid derivatives must
have been soon after his arrival there.
His laboratory reports from 27 September 1898
onward do not reveal why Dreser was then testing ace-
tylsalicylic acid on its own rather than with the other
four derivatives named in his 1899 paper. Something
must have induced him to single out acetylsalicylic
acid, and the explanation can be found in a paper
written by Eichengrün.
The claims of Arthur Eichengrün
In a paper published in Pharmazie in 1949, Eichengrün
claimed that he had instructed Hoffmann to synthesise
acetylsalicylic acid and that the latter had done so with-
out knowing the purpose of the work.9 Five years
earlier, while in Theresienstadt concentration camp, he
had typed a letter (now in the Bayer archives) with
wording similar to his 1949 paper.10 Eichengrün wrote
that his objective had been to obtain a salicylate that
would not give rise to the adverse effects (gastric irrita-
tion, nausea, or tinnitus) frequently associated with
sodium salicylate. He was present when the derivatives
of salicylic acid were tested by Dreser and came to the
conclusion that acetylsalicylic acid was superior to all
the other compounds. At a management meeting,
Eichengrün called for clinical studies to be initiated,
but Dreser used his right of veto as head of the
pharmacology division. He believed, mistakenly, that
the drug was harmful to the heart.
Convinced of the potential of acetylsalicylic acid,
Eichengrün tested it on himself, experiencing no ill
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effects. He stated that he then surreptitiously gave a
supply of it to his colleague Dr Felix Goldmann, who
then recruited physicians to evaluate the drug in strict
secrecy. Their reports were most encouraging. Tinnitus
was rare, while the antirheumatic effects were
unmistakable. But there was more—a dentist had given
the drug to a patient with a raised temperature as well
as toothache. Hardly was he out of the chair before he
exclaimed, “My toothache’s gone!” Such a rapid onset
of analgesia was unique. After a similar response was
confirmed in other patients, Goldmann sent a report to
the Bayer management. According to Eichengrün,
when Dreser was asked to comment, he scribbled on it,
“This is the usual loud-mouthing of Berlin—the
product has no value.”
Eichengrün goes on to tell us that Carl Duisberg, the
renowned head of research for Bayer, had ordered
Dreser’s results to be checked by an independent
pharmacologist. This intervention might explain why
Hoffmann synthesised stable, pure acetylsalicylic acid on
10 August 1897. If the meaning of the last sentence in
Hoffmann’s report is that acetylsalicylic acid was already
under test at that time, it would be consistent with all that
Eichengrün has written. Had acetylsalicylic acid been
tested along with the other salicylic acid derivatives in
April 1897, there would have been no written record of
its original synthesis, since Hoffmann did not write any
reports between 13 March 1896 and 5 May 1897.
Significantly, in none of his laboratory reports did he
mention the synthesis of any of the other salicylates
known to have been tested by Dreser. Presumably they
were prepared for evaluation in April 1897.
In his 1949 paper Eichengrün went on to claim
that acetylsalicylic acid was sent to several leading clin-
ics for expert assessment. Confirmation of this claim is
found in the first published clinical report on aspirin
by Kurt Witthauer of the Deaconess Hospital in Halle,
which appeared in the April 1899 issue of Die
Heilkunde.11 Revealingly, Witthauer remarked, “After
long hesitation, the factory was able to be convinced by
my favourable experiences to bring aspirin on to the
market.” Further light is thrown on this statement by
Friedrich Fischer, the head of the Elberfeld pharma-
ceutical laboratory in 1897, when he wrote that
Witthauer had energetically pushed for the introduc-
tion of the drug owing to its excellent success in the
clinic.12 It should be noted that Witthauer stated that he
had received the new salicylate compound nearly one
year earlier—that is, around April 1898.
Eichengrün claimed that Dreser was then instructed
to write a report that would give scientific credibility to
the new drug. This explains why Dreser reinvestigated
acetylsalicylic acid on its own in September 1898.
The credibility of the claims by
Eichengrün
Why did Eichengrün wait 15 years before refuting what
had been written in 1934 about the role of Hoffmann?
The answer may be found by considering Eichengrün’s
situation at that time. After the introduction of aspirin,
he had developed not only several more drugs but also
cellulose acetate, acetate silk, and acetate safety film
before leaving Bayer in 1908 to establish his own
factory in Berlin. There, he produced flame resistant
materials based on acetyl cellulose and also pioneered
the process of injection moulding of plastics.
Consequently, he enjoyed the affluent life style of a
successful industrialist, yet because he was a Jew all this
was put at risk after the Nazi party gained power.
By the time the claim that Hoffmann had initiated
the development of aspirin was published, the Nazis
had banned Jews from the civil service and from inde-
pendent positions in the professions and in economic
life. Even as a prominent industrialist, Eichengrün was
not exempt from their attentions. He was forced to take
an associate into his company to avoid loss of contracts
from state enterprises. A low profile was the order of
the day, but that was not enough to prevent his
company being forcibly transferred to another owner
in 1938. His marriage to an “Aryan” wife enabled him
to retain his freedom until 1944, when at the age of 76
he was interned for 14 months in Theresienstadt,
languishing there until its liberation by the Soviet
Army.
During the Nazi era, Eichengrün was in no position
to issue a public rebuttal of what had been published
about Hoffmann. Some insight into his feelings at that
time is given by a paragraph in his 1949 paper: “In
1941, there stood in the Hall of Honour of the chemi-
cal section of the German Museum in Munich a show-
case filled with white crystals, with the inscription,
‘Aspirin: inventors Dreser and Hoffmann’. Dreser had
nothing whatsoever to do with the discovery, and Hoff-
mann carried out my chemical instructions in the first
place without knowing the aim of the work. Next to the
showcase was a similar one filled with acetylcellulose,
today also a product of worldwide importance, whose
discovery by me it is impossible to doubt since it was
established in a series of German patents from 1901 to
1920. It was simply described by the expression
‘Acetylcellulose—Cellit’; they had refrained from nam-
ing the inventor. But, at the main entrance to the
museum there hung a large sign which forbade
non-Aryans from entering this institute! Those who
understand will read between the lines.”
In his letter from Theresienstadt, Eichengrün con-
cluded a similar paragraph with a different sentence:
“To what influences this omission is to be attributed,
can be only assumed.” There can be little doubt that he
felt that he had been written out of history because he
was a Jew. Such historical revisionism was not unknown
in the Nazi era.
Two years after the war ended, Eichengrün
celebrated his 80th birthday amid glowing tributes in
German scientific journals.13–15 He died in Berlin on 23
December 1949, in the same month that his account of
the discovery of aspirin was published. He was spared
from knowing that it would remain largely ignored for
another half century.
Conclusion
Everything that Eichengrün claimed in 1949 about the
discovery of aspirin is compatible with the chronology of
events presented here, which in turn depends to a great
extent upon the reliability of the statement by
Eichengrün that Dreser set acetylsalicylic acid aside for
18 months. This statement, however, has never been
challenged. As Eichengrün did not refer to his own role
in the discovery of aspirin in the chapter in which the
statement appeared in 1918, it would be unreasonable
History
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to argue that the source is tainted. Also, Hoffmann—who
lived until 1946 without ever publishing his own account
of the discovery of aspirin—repeatedly spoke of Dreser
setting the drug aside, albeit without indicating for how
long. But had it only been for a short period, he would
not have mentioned it.
In deciding whether it is Hoffmann or Eichengrün
who initiated the events leading to the introduction of
aspirin, the unreliability of the 1934 footnote about
Hoffmann must be balanced against the plausibility of
the 1949 paper by Eichengrün. The most reasonable
conclusion is that Arthur Eichengrün was telling the
truth when he wrote that acetylsalicylic acid was
synthesised under his direction and that the drug
would not have been introduced in 1899 without his
intervention.
F Bayer & Co was truly fortunate in having Eichen-
grün as an employee, yet it is unlikely that he would
have discovered aspirin had he not been working for
the company. Its successor, Bayer AG, had every reason
last year to celebrate proudly the centenary of the most
widely used drug in history.
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Serial homicide by doctors: Shipman in perspective
Herbert G Kinnell
The previous BMA chairman, among others, is on
record as saying that Harold Shipman is unique, yet
medicine has arguably thrown up more serial killers
than all the other professions put together, with
nursing a close second.1–4 Dentistry too has had its
notorious characters, yet among veterinarians homi-
cide seems to be almost unknown.
“Jack the Ripper,” the perpetrator of five unsolved
murders in 1888 in London, is thought to have been a
member of the medical profession, although there is
no conclusive evidence. Sir William Gull, “physician
in ordinary” to Queen Victoria, and Dr Thomas
Barnardo were prime suspects, and there were
advocates for Montague John Druitt, a barrister (he was
from a respected medical family and may have passed
himself off as a doctor); a Dr Stanley (he may have been
fictitious); the Polish Dr George Chapman (real name
Severin Klosowski); and the Russian Dr Alexander
Pedachenko.5–7 Nor has conclusive evidence been
found for Gaylord Sundheim (a psychotic who had
studied medicine) being the “mad butcher” of
Cleveland, Ohio, in the 1930s.8
The power of life and death
Yet there are enough recorded instances of multiple
murders by doctors (real or bogus) to make at least a
prima facie case that the profession attracts some
people with a pathological interest in the power of life
and death. Would be doctors with homicidal tenden-
cies include Kenneth Bianchi, one of the serial
“Hillside Stranglers” in 1978 (his cousin was the other
murderer), who had always wanted to be a psychiatrist
and indeed set himself up as a psychological
counsellor after assuming a false identity,9 and William
Henry Theodore Durrant, a San Francisco medical
student and Sunday school superintendent who
Summary points
Arguably medicine has thrown up more serial
killers than all the other professions put together
The medical profession seems to attract some
people with a pathological interest in the power
of life and death
Doctors have been responsible for killing not only
patients and strangers but members of their own
family
The political killers par excellence were the Nazi
doctors and the Japanese doctors engaged in
biological warfare
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